In: In vivo CAR-T

HN2301

MagicRNA

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CD19 CAR-T, mRNA in CD8-targeted lipid nanoparticles
How it’s given
“Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.”In the company’s words, NCT07556120 on ClinicalTrials.gov
Tested for
Generalized Myasthenia Gravis, Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
Main trialPhase 1
“This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.”In the company’s words, NCT07556120 on ClinicalTrials.gov

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 31 May 2027 Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Phase 1Recruiting 31 Dec 2027 Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow HN2301

Following is part of Solo: you see every change to HN2301 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in